Jefferies: Goley Pharmaceuticals made significant progress in the HK$3.8 target pipeline

On April 18, 2024, Jefferies released a research report stating that Glory Pharmaceuticals currently focuses on the application of ASC41 and ASC40 in NASH indications, and is awaiting the disclosure of the mid-term results of the ASC40 phase III RGBM trial in the second half of the year. ASC41 showed positive results in mid-phase II data for NASH treatment. It has similar properties to lametirol, which has been approved by the FDA, and has shown significant advantages in reducing liver fat. ASC40 has also had positive results in clinical trials for F2/F3 NASH and acne. Furthermore, Golie Pharmaceuticals decided to end

新浪港股Apr 18 22:08 ET

Hong Kong Stock Announcement Nuggets | China Overseas Development: The cumulative contract property sales of China's overseas affiliates in the first three months were about RMB 60.206 billion, down 28% year on year

China Overseas Development (00688): The cumulative contract property sales volume of China's overseas affiliated companies in the first three months was about 60.206 billion yuan, down 28% year on year; Vanke Enterprise (02202) achieved contract sales of 57.98 billion yuan in the first quarter, a decrease of 42.81% year on year

Zhitong FinanceApr 4 08:05 ET

Ascletis Discontinues Trials of FXR Agonist for Biliary Cholangitis, NASH and Hepatitis B Virus

Ascletis Pharma (HKG:1672) has decided not to proceed with further clinical trials of its farnesoid X receptor (FXR) agonist ASC42 for primary biliary cholangitis (PBC) indication, according to a fili

MT NewswiresApr 3 07:57 ET

Kerry Pharmaceutical-B (01672.HK) Announces Strategic Decision on Farnesol X Receptor (FXR) agonist ASC42

On April 3, Gelonghui Pharmaceutical-B (01672.HK) announced a strategic decision on the farnesol X receptor (FXR) agonist ASC42. After thorough analysis of the ASC42 phase II clinical trial (ClinicAlt rials.gov: NCT05190523) data for primary biliary cholangitis (PBC), the company made a strategic decision not to continue clinical trials with ASC42 for PBC. The decision was based on efficacy and safety data from the 12-week phase II study, which included three ASC42 active treatment groups (5

Gelonghui FinanceApr 3 05:02 ET

Goli Pharmaceutical-B (01672) announced its 2023 annual results, with revenue of about 56.6 million yuan, an increase of 4.6% over the previous year

Goli Pharmaceutical-B (01672) announced the results for the year ended December 31, 2023. The Group's revenue increased from 2...

Zhitong FinanceMar 25 09:15 ET

Goli Pharmaceutical-B (01672.HK) annual loss reduced to 145 million yuan

Gelonghui, March 25 | Goli Pharmaceutical-B (01672.HK) announced that for the year ended December 31, 2023, the company's revenue increased 4.6% from approximately RMB 54.1 million in the previous year to approximately RMB 56.6 million. The Group's total revenue (including revenue and other revenue and revenue) increased by 45.2% from approximately RMB 166.1 million in the previous year to approximately RMB 241.2 million. The Group's loss for the year decreased from RMB 314.8 million in the previous year to RMB 144.7 million in the same year, mainly due to (i) the increase in product sales revenue

Gelonghui FinanceMar 25 09:12 ET